Acinetobacter baumannii OXA-113 (CDC & FDA AR Bank #0308), Thigh Infection Model, CFU Data
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This assay assesses the antimicrobial efficacy of test articles in a lung infection model. The microbial counts in tissue are measured. Acinetobacter baumannii is a commensal Gram-negative bacterium that can cause life-threatening infections such as bacteremia, peritonitis, lung, and urinary tract infections. It is an important pathogen in healthcare settings. This carbapenem-resistant A. baumannii strain produces OXA-113 carbapenemase as well as ADC-30 and TEM-1D β-lactamases. It is resistant to β-lactam antibiotics, aminoglycosides, quinolones, and colistin.
SPECIES
Acinetobacter baumannii
STRAIN COMMON NAME
(#0308)
ORGANISM
Gram-negative Bacteria
INCUBATION CONDITIONS
Aerobic
NOTABLE ANTIBIOTIC RESISTANCE GENE
OXA-113
ANTIBIOTIC RESISTANCE GENES
aac(6')-Ib-AKT,aadA1,ABAF,ADC-30,ADEC,aph(6)-Id,armA,catB8,mph(E),msr(E),OXA-113,qacEdelta1,strA,sul1,TEM-1D,tet(B)
GENOMIC ACCESSION NUMBER
SAMN04901698
SOURCE
STRAIN SOURCE
CDC & FDA AR Isolate Bank
STRAIN SOURCE ID
AR Bank #0308
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 5 female specific-pathogen-free BALB/c mice, 7 weeks of age, are used. Animals are immunosuppressed by two intraperitoneal injections of cyclophosphamide, the first at 150 mg/kg 4 days before infection (day –4) and the second at 100 mg/kg 1 day before infection (day –1). On day 0, animals are inoculated intramuscularly (0.1 mL/thigh) with 1 x 10⁶ CFU/mouse of Acinetobacter baumannii (AR Bank #0308). Vehicle and/or test substances are then administered 2 and 14 hours later per the specification of the study design table. At 26 hours after inoculation, animals are euthanized with CO₂ asphyxiation and the thigh tissue is harvested from each of the test animals. The tissues are homogenized in 3 mL of PBS, pH 7.4 with a homogenizer. Homogenates, 0.1 mL, are used for serial 10-fold dilutions and plated onto nutrient agar for colony count determination.
CRITERIA FOR SIGNIFICANCE
A significant (p < 0.05) decrease in the bacterial counts of the treated animals compared to the vehicle control group or the baseline control group was considered a significant difference.
TURNAROUND TIME
STANDARD
30 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences